Evidence map›Paper›PMID 40301483›Full record

ArticleScientific reports2025

Association between serum cystatin C and chronic lung disease in middle-aged and elderly Chinese: a CHARLS cross-sectional study.

Liuyun Huang, Ling Li, Mingjie Xie, Lihua Lei, Fangmei Wei, Jianghuan Qin, Debin Huang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liuyun HuangDepartment of Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Ling LiDepartment of Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Mingjie XieDepartment of Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Lihua LeiSchool of Nursing, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Fangmei WeiSchool of Nursing, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Jianghuan QinSchool of Nursing, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Debin HuangDepartment of Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. hdeb@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dose-response relationship between cystatin C (CysC) levels and chronic lung disease (CLD) development remains unclear and warrants further investigation. A more in-depth study of the relationship between serum CysC levels and CLD prevalence based on data from the China Health and Retirement Longitudinal Study (CHARLS). A cross-sectional analysis of 10,275 middle-aged and older adults aged 45 years and older was conducted using 2015 CHARLS data. Binary logistic regression models, restricted cubic spline curves (RCS), and threshold effects analyses were used to explore the association between different CysC levels and CLD prevalence in the middle-aged and older population, and subgroup analyses were performed to verify the robustness of the findings. When CysC was used as a categorical variable, the risk of CLD was increased by 38% in the T3 group compared with T1 (P < 0.001), and when CysC was used as a continuous variable, the risk of CLD was increased by 96% for each unit increase in CysC level (P < 0.001). In addition, there was a nonlinear relationship between CysC levels and the risk of CLD prevalence (P for non-linearity < 0.012), and the risk of CLD prevalence increased significantly with increasing CysC levels when CysC levels ≥ 0.754 mg/L. When CysC ≥ 0.754 mg/L, we need to be highly concerned about the risk of developing chronic lung disease in middle-aged and older populations, and those aged 45-64 years should be the focus of screening.

Indexed as

Cystatin CLung DiseasesAgedBiomarkersChinaChronic DiseaseCross-Sectional StudiesEast Asian PeopleFemaleHumansLongitudinal StudiesMaleMiddle AgedPrevalenceRisk FactorsBiomarkersCystatin CCHARLSChronic lung diseaseCystatin CMiddle-aged and elderly people

Identifiers

PMID40301483
PMCPMC12041603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.